↓ Skip to main content
What is this page? Embed badge

Small Molecules in Hematology

Overview of attention for book
Cover of 'Small Molecules in Hematology'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Imatinib Mesylate
  3. Altmetric Badge
    Chapter 2 Dasatinib
  4. Altmetric Badge
    Chapter 3 Nilotinib
  5. Altmetric Badge
    Chapter 4 Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor
  6. Altmetric Badge
    Chapter 5 Ponatinib: A Third-Generation Inhibitor for the Treatment of CML
  7. Altmetric Badge
    Chapter 6 Ruxolitinib
  8. Altmetric Badge
    Chapter 7 Ibrutinib
  9. Altmetric Badge
    Chapter 8 Pomalidomide
  10. Altmetric Badge
    Chapter 9 Enasidenib
  11. Altmetric Badge
    Chapter 10 Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis
  12. Altmetric Badge
    Chapter 11 Venetoclax: Targeting BCL2 in Hematological Cancers
  13. Altmetric Badge
    Chapter 12 Idelalisib
  14. Altmetric Badge
    Chapter 13 Carfilzomib
  15. Altmetric Badge
    Chapter 14 Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
Attention for Chapter 14: Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
17 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
Chapter number 14
Book title
Small Molecules in Hematology
Published in
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
DOI 10.1007/978-3-319-91439-8_14
Pubmed ID
30069636
Book ISBNs
978-3-31-991438-1, 978-3-31-991439-8
Authors

Katharina Kriegsmann, Mark Kriegsmann, Mathias Witzens-Harig, Kriegsmann, Katharina, Kriegsmann, Mark, Witzens-Harig, Mathias

Abstract

The Bruton's tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of distinct B-cell malignancies. To overcome off-target side effects of and emerging resistances to ibrutinib, more selective second-generation BTK inhibitors were developed. Acalabrutinib is a novel second-generation BTK inhibitor and has shown promising safety and efficacy profiles in phase 1/2 clinical trials in patients with relapsed CLL and pretreated MCL. Recently, acalabrutinib was approved by the FDA for treatment of adult patients with MCL who received at least one prior therapy. However, clinical trials on a direct comparison between ibrutinib and acalabrutinib and on combination treatment options with other agents as CD20 antibodies are warranted.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 18%
Other 2 12%
Student > Doctoral Student 2 12%
Researcher 2 12%
Student > Ph. D. Student 1 6%
Other 1 6%
Unknown 6 35%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Biochemistry, Genetics and Molecular Biology 2 12%
Immunology and Microbiology 2 12%
Agricultural and Biological Sciences 2 12%
Chemical Engineering 1 6%
Other 2 12%
Unknown 6 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2020.
All research outputs
#15,542,250
of 23,098,660 outputs
Outputs from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#96
of 172 outputs
Outputs of similar age
#270,160
of 442,681 outputs
Outputs of similar age from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#12
of 22 outputs
Altmetric has tracked 23,098,660 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 172 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,681 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.